防晒霜活性成分血浆浓度的随机临床试验
这项在健康参与者中开展的随机临床试验评估了4种防晒产品中6种活性成分的全身吸收和药代动力学。结果显示,所有6种活性成分在单次使用后血浆浓度即超过0.5 ng/mL的FDA阈值,最常见不良事件为皮疹。
要点
- 所有6种防晒活性成分在单次使用后血浆浓度均超过0.5 ng/mL。
- 阿伏苯宗最高血浆浓度因剂型而异,乳液为7.1 ng/mL。
- 氧苯酮乳液浓度达258.1 ng/mL,气雾剂为180.1 ng/mL。
核心结论
- 所有测试的6种防晒活性成分均被全身吸收,血浆浓度超过FDA可能豁免额外安全性研究的阈值。
- 这些发现不表明个体应避免使用防晒霜。
研究设计与样本
- 随机临床试验在临床药理学单位(威斯康星州West Bend)进行,纳入48名健康参与者。
- 研究于2019年1月至2月开展,参与者随机分配至4种防晒产品之一,每种12人。
- 产品包括乳液、气雾喷雾、非气雾喷雾和泵喷雾。
- 第1天0小时以2 mg/cm²涂抹于75%体表面积,第2至4天每2小时涂抹4次。
- 每名参与者21天内采集34次血样。
主要发现
- 44名(92%)参与者完成试验;平均年龄38.7岁(SD 13.2),24名女性(50%)。
- 所有6种活性成分的几何平均最大血浆浓度均大于0.5 ng/mL,单次使用后第1天即超过该阈值。
- 阿伏苯宗总体最大血浆浓度:乳液7.1 ng/mL(CV 73.9%),气雾喷雾3.5 ng/mL(CV 70.9%),非气雾喷雾3.5 ng/mL(CV 73.0%),泵喷雾3.3 ng/mL(CV 47.8%)。
- 氧苯酮浓度:乳液258.1 ng/mL(CV 53.0%),气雾喷雾180.1 ng/mL(CV 57.3%)。
- 奥克立林浓度:乳液7.8 ng/mL(CV 87.1%),气雾喷雾6.6 ng/mL(CV 78.1%),非气雾喷雾6.6 ng/mL(CV 103.9%)。
临床怎么用
- 临床医生应告知患者防晒霜活性成分可全身吸收,但不应因此停用防晒霜。
- 对于需长期大面积使用防晒霜的人群,可关注FDA对防晒活性成分安全性研究的更新。
局限性
- 研究在临床药理学单位进行,环境条件与真实世界使用可能不同。
- 样本量较小(48人),且仅测试了4种特定产品。
- 未评估长期健康影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: A prior pilot study demonstrated the systemic absorption of 4 sunscreen active ingredients; additional studies are needed to determine the systemic absorption of additional active ingredients and how quickly systemic exposure exceeds 0.5 ng/mL as recommended by the US Food and Drug Administration (FDA). OBJECTIVE: To assess the systemic absorption and pharmacokinetics of the 6 active ingredients (avobenzone, oxybenzone, octocrylene, homosalate, octisalate, and octinoxate) in 4 sunscreen products under single- and maximal-use conditions. DESIGN, SETTING, AND PARTICIPANTS: Randomized clinical trial at a clinical pharmacology unit (West Bend, Wisconsin) was conducted in 48 healthy participants. The study was conducted between January and February 2019. INTERVENTIONS: Participants were randomized to 1 of 4 sunscreen products, formulated as lotion (n = 12), aerosol spray (n = 12), nonaerosol spray (n = 12), and pump spray (n = 12). Sunscreen product was applied at 2 mg/cm2 to 75% of body surface area at 0 hours on day 1 and 4 times on day 2 through day 4 at 2-hour intervals, and 34 blood samples were collected over 21 days from each participant. MAIN OUTCOMES AND MEASURES: The primary outcome was the maximum plasma concentration of avobenzone over days 1 through 21. Secondary outcomes were the maximum plasma concentrations of oxybenzone, octocrylene, homosalate, octisalate, and octinoxate over days 1 through 21. RESULTS: Among 48 randomized participants (mean [SD] age, 38.7 [13.2] years; 24 women [50%]; 23 white [48%], 23 African American [48%], 1 Asian [2%], and 1 of unknown race/ethnicity [2%]), 44 (92%) completed the trial. Geometric mean maximum plasma concentrations of all 6 active ingredients were greater than 0.5 ng/mL, and this threshold was surpassed on day 1 after a single application for all active ingredients. For avobenzone, the overall maximum plasma concentrations were 7.1 ng/mL (coefficient of variation [CV], 73.9%) for lotion, 3.5 ng/mL (CV, 70.9%) for aerosol spray, 3.5 ng/mL (CV, 73.0%) for nonaerosol spray, and 3.3 ng/mL (CV, 47.8%) for pump spray. For oxybenzone, the concentrations were 258.1 ng/mL (CV, 53.0%) for lotion and 180.1 ng/mL (CV, 57.3%) for aerosol spray. For octocrylene, the concentrations were 7.8 ng/mL (CV, 87.1%) for lotion, 6.6 ng/mL (CV, 78.1%) for aerosol spray, and 6.6 ng/mL (CV, 103.9%) for nonaerosol spray. For homosalate, concentrations were 23.1 ng/mL (CV, 68.0%) for aerosol spray, 17.9 ng/mL (CV, 61.7%) for nonaerosol spray, and 13.9 ng/mL (CV, 70.2%) for pump spray. For octisalate, concentrations were 5.1 ng/mL (CV, 81.6%) for aerosol spray, 5.8 ng/mL (CV, 77.4%) for nonaerosol spray, and 4.6 ng/mL (CV, 97.6%) for pump spray. For octinoxate, concentrations were 7.9 ng/mL (CV, 86.5%) for nonaerosol spray and 5.2 ng/mL (CV, 68.2%) for pump spray. The most common adverse event was rash, which developed in 14 participants. CONCLUSIONS AND RELEVANCE: In this study conducted in a clinical pharmacology unit and examining sunscreen application among healthy participants, all 6 of the tested active ingredients administered in 4 different sunscreen formulations were systemically absorbed and had plasma concentrations that surpassed the FDA threshold for potentially waiving some of the additional safety studies for sunscreens. These findings do not indicate that individuals should refrain from the use of sunscreen. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03582215.
引用
- Matta MK, Florian J, Zusterzeel R, et al. Effect of Sunscreen Application on Plasma Concentration of Sunscreen Active Ingredients: A Randomized Clinical Trial. JAMA. 2020. PMID: 31961417. doi:10.1001/jama.2019.20747
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。